Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SNY

Sanofi ADR

Apr 10 • 04:00PM ET

46.76

-0.32 -0.68 %

Healthcare • Drug Manufacturers - General • France • NASD

Peers: NVS PFE MRK GSK BMY LLY AZN-D JNJ ABBV AMGN

| Held by: PVAL PPH FVD FENI AVDE PID BASV BDYN GMOI BUSA

Scroll to Statements

Index	-	P/E	19.59	EPS (ttm)	2.39	Insider Own	0.01%	Shs Outstand	2.42B	Perf Week	-2.36%
Market Cap	112.24B	Forward P/E	8.89	EPS next Y	5.26	Insider Trans	0.00%	Shs Float	2.40B	Perf Month	6.42%
Enterprise Value	127.50B	PEG	1.24	EPS next Q	1.03	Inst Own	9.32%	Short Float	0.31%	Perf Quarter	-2.85%
Income	5.84B	P/S	2.27	EPS this Y	5.57%	Inst Trans	-3.58%	Short Ratio	1.82	Perf Half Y	-4.18%
Sales	49.41B	P/B	1.35	EPS next Y	6.63%	ROA	3.87%	Short Interest	7.40M	Perf YTD	-3.51%
Book/sh	34.71	P/C	12.45	EPS next 5Y	7.19%	ROE	6.76%	52W High	55.73 -16.10%	Perf Year	-5.84%
Cash/sh	3.75	P/FCF	10.71	EPS past 3/5Y	-11.86% -15.52%	ROIC	5.71%	52W Low	43.32 7.94%	Perf 3Y	-14.97%
Dividend Est.	2.48 (5.31%)	EV/EBITDA	6.56	Sales past 3/5Y	2.90% 3.69%	Gross Margin	65.90%	Volatility	1.48% 1.63%	Perf 5Y	-7.41%
Dividend TTM	2.21 (4.73%)	EV/Sales	2.58	EPS Y/Y TTM	-0.23%	Oper. Margin	26.10%	ATR (14)	0.90	Perf 10Y	10.98%
Dividend Ex-Date	May 09, 2025	Quick Ratio	0.73	Sales Y/Y TTM	11.19%	Profit Margin	11.81%	RSI (14)	52.61	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	1.09	EPS Q/Q	-29.64%	SMA20	1.59%	Beta	0.38	Target Price	56.12
Payout	-	Debt/Eq	0.28	Sales Q/Q	28.69%	SMA50	0.66%	Rel Volume	0.55	Prev Close	47.08
Employees	76493	LT Debt/Eq	0.22	Earnings	Apr 23 BMO	SMA200	-2.87%	Avg Volume	4.07M	Price	46.76
IPO	Jul 01, 2002	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.11% 3.35%	Trades		Volume	2,230,467	Change	-0.68%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-26	Downgrade	BofA Securities	Buy → Neutral
Jan-27-26	Initiated	Citigroup	Neutral
Jan-16-26	Downgrade	UBS	Buy → Neutral
Jan-06-26	Downgrade	Barclays	Overweight → Equal Weight
Dec-09-25	Downgrade	Guggenheim	Buy → Neutral
Dec-08-25	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$58
Sep-02-25	Upgrade	Deutsche Bank	Hold → Buy
Aug-08-25	Upgrade	JP Morgan	Neutral → Overweight
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$65
Mar-21-25	Initiated	Goldman	Neutral	$65
Jan-30-25	Upgrade	Deutsche Bank	Sell → Hold
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell

Show Previous Ratings

Apr-07-26 01:36PM	Sanofis bispecific scores in respiratory diseases but fails in eczema (Clinical Trials Arena)
04:34AM	Sanofi immune drug hopeful posts mixed results in mid-stage tests (BioPharma Dive)
Mar-30-26 05:31AM	Sanofi eczema drug weighed down by mixed results, safety concerns (BioPharma Dive)
Mar-27-26 07:56AM	AstraZeneca lung drug gets surprise win in COPD trials (BioPharma Dive)
Mar-24-26 06:36AM	Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody (Pharmaceutical Business Review)
08:15AM	Loading…
Mar-23-26 08:15AM	Earendil Labs lands $787m to fund biologics development push (Pharmaceutical Technology)
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
06:16AM	FDA seeks feedback on voucher program; Study data lift overhang on Insmed shares (BioPharma Dive)
Mar-20-26 09:13AM	Earendil Labs, an AI-powered drugmaker, hauls in $787M (BioPharma Dive)
Mar-17-26 02:32PM	Transient but transformative: Sanofis mRNA CAR-T enters in vivo race (Pharmaceutical Technology)
Mar-12-26 11:08PM	Vaxart Inc (VXRT) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... (GuruFocus.com)
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-09-26 08:31PM	Analyst Report: Sanofi (Morningstar Research)
12:07PM	Dianthus Therapeutics Has Appreciated 13-Fold Over Two Years. What's Going On? (Investor's Business Daily)
09:35AM	Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026? (Zacks)
09:22AM	Loading…
09:22AM	Dianthus Therapeutics Stock Rallies-Rare Disease Study Success Fuels Optimism (Benzinga)
Mar-06-26 02:33AM	Germanys Merck KGaA Expects Currency Headwinds to Weigh on Earnings (The Wall Street Journal)
Mar-05-26 08:02PM	Euroapi SA (EAPIF) Full Year 2025 Earnings Call Highlights: Strong EBITDA Growth Amid Sales ... (GuruFocus.com)
02:11PM	Podcast: Sanofis head of clinical supply chain operations on evolving the clinical trial supply model (Clinical Trials Arena)
Mar-04-26 02:02PM	Sanofi bets on Sino Biopharms transplant drug in $1.5bn licensing deal (Pharmaceutical Technology)
06:57AM	Blackstone puts $400M into Teva, Sanofi gut disease drug (BioPharma Dive)
Mar-03-26 10:50AM	Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU (Zacks)
10:00AM	Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan (Zacks)
04:46AM	Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer (Zacks)
Mar-02-26 09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
08:39AM	4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam (Zacks)
08:16AM	Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial (The Wall Street Journal)
07:49AM	MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot (Zacks)
05:59AM	Sanofi receives CHMP recommendation for Dupixent approval in Europe (Pharmaceutical Business Review)
Mar-01-26 04:26AM	Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval (Insider Monkey)
01:32PM	Loading…
Feb-28-26 01:32PM	Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 (MarketBeat)
Feb-27-26 02:20PM	What's Going On With Novavax Stock On Friday? (Benzinga)
09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
09:02AM	DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus (Zacks)
08:26AM	Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates (Zacks)
01:54AM	Novavax Stock Hits Over 1-Year High: Is Sanofis Flu-COVID Shot The Post-Pandemic Growth Driver? (New feeds test provider finance)
12:07AM	Novavax Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 08:00PM	Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Call Highlights: Strategic Milestones and ... (GuruFocus.com)
05:03PM	Kymera Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:11PM	Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... (GuruFocus.com)
04:08PM	Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
08:46AM	Novavax shares subdued despite earnings, revenue beat (Investing.com)
08:30AM	Novavax, Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-25-26 05:25PM	Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk (MarketBeat)
05:25PM	Recursion Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
01:43PM	CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans (Zacks)
12:42AM	FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis (RTT News)
Feb-24-26 01:47PM	Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition (Benzinga)
11:35AM	BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market (Zacks)
09:02AM	IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? (Zacks)
09:00AM	This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug (Barrons.com)
Feb-23-26 04:30PM	Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA (Insider Monkey)
07:38AM	Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff. (Barrons.com)
03:38AM	Merck to split cancer, specialty drug businesses in leadership shakeup (BioPharma Dive)
Feb-20-26 03:13PM	Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit (Insider Monkey)
01:36PM	Ex-Trump official-ran Altesa secures $75m in Series B funding round (Pharmaceutical Technology)
Feb-19-26 10:30AM	Moderna Stock Jumps After FDA Reverses Course on Flu Shot (Zacks)
Feb-18-26 10:10AM	FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer (Benzinga)
08:12AM	Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026? (Zacks)
Feb-17-26 09:15AM	Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes (Benzinga)
08:30AM	Sanofi announces leadership evolution in Specialty Care Business Unit (PR Newswire)
07:04AM	Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients (Benzinga)
Feb-16-26 08:59AM	RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? (Zacks)
04:40AM	Looking for Dividends? Consider Europe. (Barrons.com)
Feb-15-26 04:41AM	Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit (MarketBeat)
Feb-14-26 11:08AM	Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight (MarketBeat)
Feb-13-26 05:03PM	Health Care Roundup: Market Talk (The Wall Street Journal)
12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
08:23AM	Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors (Benzinga)
Feb-12-26 04:15PM	Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson (Investor's Business Daily)
03:30PM	Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant (Reuters Videos)
01:17PM	Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head (Pharmaceutical Technology)
11:08AM	Sanofi Shares Fall After CEO Change (The Wall Street Journal)
09:30AM	Will Eylea Sales Decline Weigh on REGN's Top Line in 2026? (Zacks)
06:28AM	Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor' (Benzinga)
06:27AM	Sanofi replaces chief Paul Hudson with Merck executive after R&D woes (Financial Times)
06:22AM	Sanofi cut to neutral at BofA on CEO change, shares drop over 6% (Investing.com)
05:55AM	Sanofi, looking for more rigor, swaps CEO Hudson for ex-Merck KGaA chief Garijo (BioPharma Dive)
04:36AM	Sanofi says board has removed CEO Paul Hudson (AFP)
02:42AM	Sanofi Names Merck KGaAs Garijo to Replace Hudson as CEO (The Wall Street Journal)
Feb-11-26 02:23PM	NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review (Benzinga)
12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
08:30AM	Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? (Zacks)
07:53AM	Evommunes stock rallies 70% on Phase IIa eczema data (Clinical Trials Arena)
07:35AM	Why Is Nektar Therapeutics Stock Gaining Wednesday? (Benzinga)
06:44AM	Moderna shares fall as FDA declines to review new flu vaccine (Reuters)
05:21AM	FDA Refuses To Review Moderna's Influenza Shot Application (Benzinga)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily)
10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
09:07AM	Evommune Nearly Doubles Has Dupixent Met Its Match In Eczema? (Investor's Business Daily)
08:00AM	Sanofi CEO: The enterprise AI shift will reshape pharma in 2026 (Fortune)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
Feb-08-26 04:27AM	?Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook (Insider Monkey)
Feb-06-26 09:26AM	Have originator medicines list prices started to drop in the US? (Pharmaceutical Technology)
07:35AM	Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. (Barrons.com)
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
07:55AM	Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 (Insider Monkey)
Feb-02-26 06:08PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your Finviz experience